From 1 July 2024, the meningococcal ACWY vaccine MenQuadfi will be funded on the National Immunisation Program (NIP).
Invasive meningococcal disease (IMD) is caused by infection with the bacteria Neisseria meningitidis. It can result meningitis and septicaemia, as well as other infections like pneumonia, arthritis and conjunctivitis. Children under 2 years have the highest incidence of meningococcal disease in Australia, with another peak among adolescents and young adults aged 15 to 24 years.
MenQuadfi replaces Nimenrix for the adolescent age group (year 10 equivalent and up to 19 years for catch up). Children aged 12 months and those with specific medical conditions will continue to receive the Nimenrix vaccination on the NIP.
MenQuadfi was registered for use by the Therapeutic Goods Administration (TGA) in 2020. It is given as a single 0.5 mL dose, to be administered intramuscularly.
NIP: Meningococcal ACWY vaccines – updates for 1 July 2024
TGA: MenQuadfi
MVEC：脑膜炎球菌